Free Trial
NASDAQ:CLSD

Clearside Biomedical Q1 2025 Earnings Report

Clearside Biomedical logo
$0.86 +0.01 (+1.23%)
As of 05/15/2025 04:00 PM Eastern

Clearside Biomedical EPS Results

Actual EPS
-$0.11
Consensus EPS
-$0.12
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Clearside Biomedical Revenue Results

Actual Revenue
$2.33 million
Expected Revenue
$0.20 million
Beat/Miss
Beat by +$2.13 million
YoY Revenue Growth
N/A

Clearside Biomedical Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
Wednesday, May 14, 2025
Conference Call Time
4:00PM ET

Clearside Biomedical Earnings Headlines

This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
See More Clearside Biomedical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Clearside Biomedical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Clearside Biomedical and other key companies, straight to your email.

About Clearside Biomedical

Clearside Biomedical (NASDAQ:CLSD), a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

View Clearside Biomedical Profile

More Earnings Resources from MarketBeat